FIELD: biotechnology.
SUBSTANCE: invention relates to production of a conjugate containing trastuzumab and a conjugated fragment consisting of monomethyl auristatin E (MMAE) and PEG-linker.
EFFECT: obtained conjugate can be used for treating a malignant tumor.
14 cl, 5 tbl, 12 ex, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| HOMOGENEOUS ANTIBODY AND DRUG CONJUGATES PRODUCED BY ENZYMATIC METHODS | 2015 |
|
RU2796266C2 |
| GLYCOSYLATED CONGUGATES OF MOLECULES WITH REPEATING MOTIF | 2010 |
|
RU2574201C2 |
| ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | 2015 |
|
RU2674979C2 |
| CONJUGATED IMMUNOGLOBULINS WITH C-TERMINAL LYSINE | 2016 |
|
RU2747581C2 |
| G-CSG CONJUGATES | 2001 |
|
RU2290411C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY MEANS OF GLYCOENGINEERING | 2014 |
|
RU2711935C2 |
| INTERLEUKIN 10 CONJUGATES AND OPTIONS FOR THEIR USE | 2019 |
|
RU2815891C2 |
| COVALENT BONDED POLYPEPTIDE TOXIN AND ANTIBODY CONJUGATES | 2014 |
|
RU2682754C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| COMBINATION THERAPY OF AFUCOSYLATED CD20 ANTIBODY WITH CD79b ANTIBODY-DRUGS CONJUGATE | 2014 |
|
RU2670971C9 |
